Dimerix
- Short interest
- 0.05%
- +0.04 pp 30d
- as of 22 Sept 2026
- Reported shorts
- 271K
- Shares on issue
- 600.397M
Dimerix (DXB) Short Interest
Dimerix (ASX:DXB) had 0.05% of shares reported as short positions as of 22 Sept 2026, representing 270,986 shares. Dimerix operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Dimerix
Dimerix is a clinical-stage biopharmaceutical company leveraging its proprietary Receptor-HIT platform to develop patient-preferred pharmaceutical products for global markets. Their focus is on identifying and developing drugs for areas with unmet needs, particularly in inflammatory diseases affecting the kidney and lungs.
Company profile →Dimerix (ASX:DXB) has 0.05% of its shares on issue reported as short positions as of 22 Sept 2026, or about 270,986 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.50% in March 2025. DXB is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads DXB today
- Zanger BreakoutNot a candidate
- CAN SLIMNot a candidate
- Minervini Trend TemplateWatchScore 6rank 1669 of 1716
- Crowded-Short BreakoutNot a candidate
- Quality compoundersWatchScore 15rank 968 of 1669
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
DXB fundamentals
In the year to 30 Jun 2026, Dimerix (ASX:DXB) recorded revenue of A$4.4M and a net loss after tax of A$29.8M. A year earlier it recorded revenue of A$5.6M and a net loss after tax of A$13.3M. Year-on-year growth: revenue −22.1% (FY). Net margin −685.3% (FY). Figures are in AUD, the company's reporting currency; source: Yahoo Finance, as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest DXB news
All news- Dimerix at Canaccord Drug & Device and Ignite Conferences
asx · 11 Oct 2026
- Is Dimerix (ASX:DXB) Long-Term Kidney Data Building Momentum?
kalkine · 7 Oct 2026
- Dimerix Achieves First Patient Completion Milestone for DMX-200 Clinical Program
smallcaps · 5 Oct 2026
Company details
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss DXB
Start a research thread or post the first pulse update